Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A144510 from our risk checks.
GC Cell Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩32,800.00 |
52 Week High | ₩48,800.00 |
52 Week Low | ₩27,700.00 |
Beta | 0.99 |
11 Month Change | 14.29% |
3 Month Change | -12.77% |
1 Year Change | -10.63% |
33 Year Change | -66.01% |
5 Year Change | 7.36% |
Change since IPO | -31.81% |
Recent News & Updates
Recent updates
We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative
Mar 19We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its Debt
Feb 22Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?
Jan 18Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?
Dec 14Shareholder Returns
A144510 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -1.1% | 3.9% | -4.0% |
1Y | -10.6% | 36.7% | 2.2% |
Return vs Industry: A144510 underperformed the KR Biotechs industry which returned 36.7% over the past year.
Return vs Market: A144510 underperformed the KR Market which returned 2.2% over the past year.
Price Volatility
A144510 volatility | |
---|---|
A144510 Average Weekly Movement | 4.7% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A144510 has not had significant price volatility in the past 3 months.
Volatility Over Time: A144510's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 752 | James Park | www.gccell.com |
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC.
GC Cell Corporation Fundamentals Summary
A144510 fundamental statistics | |
---|---|
Market cap | ₩492.89b |
Earnings (TTM) | -₩6.80b |
Revenue (TTM) | ₩186.62b |
2.6x
P/S Ratio-72.5x
P/E RatioIs A144510 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A144510 income statement (TTM) | |
---|---|
Revenue | ₩186.62b |
Cost of Revenue | ₩135.95b |
Gross Profit | ₩50.67b |
Other Expenses | ₩57.47b |
Earnings | -₩6.80b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -452.68 |
Gross Margin | 27.15% |
Net Profit Margin | -3.65% |
Debt/Equity Ratio | 11.2% |
How did A144510 perform over the long term?
See historical performance and comparison